Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis

Launched by REGION SKANE · Oct 11, 2021

Keywords

ClinConnect Summary

This clinical trial is studying the effects of two different treatments for latent tuberculosis (a type of TB that doesn't cause symptoms but can become active later). The researchers want to find out if taking rifampicin for 4 months increases the risk of developing a resistant form of Staphylococcus aureus, a common bacteria, compared to those who take isoniazid for 6-9 months. They will do this by collecting samples from participants before, during, and after their treatment to check for any changes in the bacteria that might make it resistant to rifampicin. They are also interested in seeing if people living with someone who has rifampicin-resistant Staphylococcus aureus might catch it themselves.

To participate in this trial, you need to have been diagnosed with latent tuberculosis and be starting treatment with either rifampicin or isoniazid. There are no specific exclusions based on other health conditions, but you will need to give your consent to be part of the study. If you choose to participate, you can expect to provide swab samples periodically throughout your treatment, and your contribution will help researchers understand the risks associated with these treatments better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • diagnosed with latent tuberculosis
• • prescribed either 4 months rifampicin or 6-9 months isoniazide
• • informed consent
• Exclusion Criteria:
• • none